

Denmark Suspends Use of AstraZeneca COVID Vaccine. "Serious Cases of Blood Clots"

An unconfirmed number of patients have developed blood clots after receiving the shot, according to health authorities. Iceland has also stopped administering the shot.

By <u>DW</u>

Region: <u>Europe</u>
Theme: Science and Medicine

Global Research, March 11, 2021

<u>DW</u>

All Global Research articles can be read in 27 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

The Danish Health Authority on Thursday <u>halted the use of the AstraZeneca coronavirus</u> <u>vaccine</u> for 14 days.

It follows reports of "serious cases of blood clots among vaccinated people," a statement read.

The Danish Health Authority stopped short of saying there was a direct link between the vaccine and the blood clots, "at the time being."

Shortly after the announcement, Iceland followed suit.

Danish, EU authorities launch an investigation

The Danish Medicines Agency said it had launched an investigation into the vaccine.

The probe is being carried out by corresponding agencies in other EU-countries as well as the European Medicines Agency (EMA).

The EMA is in charge of the evaluation and supervision of medicinal products in the EU.

"Both we and the Danish Medicines Agency have to respond to reports of possible serious side-effects, both from Denmark and other European countries," the director of the Danish Health Authority, Soren Brostrom, said in a statement.

Read Complete Article on Deutsche Welle

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Children's Health Defense

The original source of this article is <u>DW</u> Copyright © <u>DW</u>, <u>DW</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: DW

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca